Supernus' depression treatment fails mid-stage trial
18/02/2025 21:35
Feb 18 (Reuters) - Supernus Pharmaceuticals SUPN.O said on Tuesday its depression treatment failed a mid-stage trial as it did not meet the main goal of reduction in depressive symptoms. (Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing